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ABSTRACT
GLI3 is an important protein traditionally found in the Sonic Hedgehog pathway. It is
involved in numerous events that take place during embryogenesis such as the differentiation and
patterning of cells in the body. Monocytes are important innate immune cells which infiltrate the
site of inflammation when a pathogen invades our body. Gli3 has also been shown to be
upregulated in monocytes following pathogen stimulation, suggesting Gli3 could have an
important role in mediating the release of inflammatory signals known as cytokines. The histone
acetylase protein p300 traditionally acetylates histones to epigenetically modify them to allow
DNA unwinding and subsequently gene expression. A physical interaction between p300 and
GLI3 was shown in cancer cells and indicates that they could work together to modulate
transcription of target genes, but no evidence of an interaction between these two proteins has
been observed in other cell types. This thesis investigates how GLI3 and p300 work together in
human monocytes to modulate inflammatory cytokine production. Quantitative PCR shows that
GLI3 and p300 modulate pro-inflammatory cytokine expression, and both genes must be
knocked down to decrease this cytokine expression. In addition, both GLI3 and p300 are
required for CCL2 promoter activation in monocytes. Furthermore, GLI3 and p300 modulate
CCL2 at the level of secretion. However, there was no synergistic effect of GLI3 and p300.
Therefore, I attempted to clone GLI3 into a plasmid that expresses an engineered biotin ligase
that promiscuously biotinylates nearby proteins known as TurboID. Using GLI3-TurboID, I can
isolate biotinylated proteins and run mass spectrometry to identify novel proteins that GLI3
interacts with, furthering my potential research strategies. The data shown here is a step forward
in understanding how the GLI proteins interact with the immune system during inflammatory
conditions.
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INTRODUCTION
Innate Immunity and Inflammation
There are two major parts of the immune system: innate and adaptive immunity.
Adaptive immunity learns from past experiences involving specific pathogens and responds
better to those pathogens upon subsequent interactions. On the other hand, innate immunity is the
body’s first defense system which consists of generic mechanisms against all harmful materials
that enter the body. There is no specificity involved with innate immunity and each encounter is
handled in generally the same way (Kasamatsu. 2012). The first barrier of innate immunity is
actually the epithelial layer of skin, providing a physical barrier to keep antigens outside our
body (Chaplin, 2010). Other aspects of this include mucosal tissues that overlay the
gastrointestinal tract and is meant to slough off ingested contaminants. Even so, foreign particles
still find ways to enter the body and initiate a host response.
The innate immune response is initially triggered when a circulating granulocyte called a
neutrophil, recognizes and engulfs a foreign microbe. A large number of neutrophils will then
migrate to the area to overwhelm the invading microbe and release a web of nuclear material
known as neutrophil extracellular traps (NETs). This influx of cells is the basis for the
inflammation response which takes place when an infection is first caught by the white blood
cells (Rosales, 2018). On the outermost surface of the body, infection sites can be seen as
swollen and red, a visual indicator that your cells are fighting off the invading pathogen.
One of the next cell types to show up are monocytes and macrophages. These cells are
exceptionally good at phagocytosis of foreign microbes. They can detect tissue damage or
foreign microbe presence using surface receptors known as pattern recognition receptors (PRRs)
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(Newton & Dixit. 2012). These cells sense pathogen-associated molecular patterns and damageassociated molecular patterns (PAMPs and DAMPs) and will process these signals to mount a
full immune response (Kaisho and Akira 2004). Since DAMPs are molecules that would
normally be found within cells, it is obvious that they don’t belong in circulation and are easily
recognized by innate immune cells. Alternatively, PAMPs are conserved pieces of pathogens
such as the lipopolysaccharide that makes up the cell membrane of gram-negative bacteria
(Newton & Dixit, 2012). The PRRs on innate immune cells can also recognize these and initiate
an appropriate defense against the invading pathogen.
Monocytes are innate white blood cells that circulate throughout the body searching for
foreign antigen. Upon encountering antigen, they differentiate into phagocytic macrophages
(Italiani and Boraschi 2014). Monocytes express PRRs on their surface that sense PAMPs and
DAMPs (Kaisho and Akira 2004). Toll-like receptors (TLRs) are a family of PRR that are both
complex and necessary to activate an inflammatory response in the cell in response to foreign
pathogens. Upon LPS ligand binding, TLR4 transmits signal through myeloid differentiation
factor 88 (MyD88) or TIR-domain-containing adaptor-inducing interferon-γ (TRIF) adaptor
proteins (Azam et al. 2019). This signal cascade continues to activate NF-κB, p38, MAPK, and
IRF3, initiating the production of pro-inflammatory cytokines like IFN type-1, TNFα, IL-6, IL12, and IL-1β, among others (Swanson et al. 2020). Beyond TLR4, there are many other cell
receptors that recognize different types of PAMPs and DAMPs.
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The GLI family and hedgehog signaling
The GLI family includes three members: GLI1, GLI2 and GLI3. The GLI1 gene was first
discovered in humans as a highly expressed gene in human glioma, a tumor found in the glial
cells of the brain (Kinzler, et al. 1987). Later, researchers identified GLI2 and GLI3 by probing
for the zinc finger region on the GLI gene (Ruppert et al. 1988). Mutations in GLI3 have been
identified in several human malformation syndromes, including Greig cephalopolysyndactyly
syndrome (GCPS), a genetic disorder characterized by polydactyly and abnormal development in
the craniofacial area (Vortkamp, et al. 1991). Another common developmental disorder caused
by a GLI3 mutation downstream of its zinc finger is known as Pallister-Hall syndrome (PHS),
which is associated with polydactyl and other developmental malformations (Bose et al. 2002). It
was not until 1996 where the GLIs were described as functional, regulated proteins of the sonic
hedgehog (HH) pathway (Marigo, et al. 1996). Of the three GLI proteins, only GLI2 and GLI3
are able to act as repressors of hedgehog signaling because they contain repressor domains in
their N-terminal region, something GLI1 lacks (Tsaney et al. 2009). However, all three GLIs are
able activate gene transcription because of their C-terminal transcriptional activation domain
(Tasaney et al. 2009, Hui and Angers 2011). GLI proteins are often characterized as zinc-finger
transcription factors because of the zinc-finger domain located toward their N-terminal side. This
structural motif helps to stabilize the fold of many eukaryotic transcription factors and their
DNA-binding domains (Payletich and Pabo 1991).
As mentioned, GLI proteins are an integral part of an important pathway known to be
involved in differentiation and development of cells during embryogenesis and is referred to as
the hedgehog signaling pathway. After birth, HH signaling is turned off and only used in stem
cells when the body needs to regenerate or repair specific tissues. This principal signaling
3

pathway is overseen by the 12-pass transmembrane protein receptor known as patched (PTCH)
(Torroja et al. 2004). In the pathway’s ‘off’ state, PTCH inhibits an adjacent G-protein coupled
receptor smoothened (SMO) from transducing signals to downstream pathway components in the
cytoplasm of cells (Arensdorf et al. 2016). In this condition, protein kinase A (PKA), casein
kinase 1 (CK1) and glycogen synthase kinase 3β (GSK3β) phosphorylate two of the main
effector proteins of this pathway, GLI2 and GLI3 (Pietrobono et al. 2019). GLI proteins are held
in the cytoplasm by suppressor of fused (SUFU) and undergo partial proteasomal degradation
after being phosphorylated. After dissociating from SUFU, the newly truncated forms of GLI2/3
then translocate into the nucleus, bind DNA, and inhibit the expression of HH target genes
(Pietrobono et al. 2019, Niewaidomski et al. 2019). However, once the hedgehog ligand binds to
PTCH, there is no longer any inhibition of smoothened, allowing it to accumulate and promote
signaling cascades to the GLI transcription factors (Arensdorf et al. 2016, Pietrobono et al.
2019). The cluster of phosphorylated proteins breaks apart, no longer labeling GLIs for
ubiquitination, and SUFU again dissociates from the GLI proteins allowing them to leave the
cytosol. Now, a full-length version of GLI2/3 (or GLI1) enters the nucleus and activates
transcription of target genes that promote further pathway activation like PTCH and GLI1
(Pietrobono, et al. 2019, Gupta et al. 2010). It is important to note that GLI2 is considered the
most potent activator of HH signaling, and GLI3 is thought of as the most potent inhibitor of HH
signaling (Sasaki et al. 1999, Zeng et al. 2010).
While the main function of the GLI proteins is to support stem cell development and
differentiation through the HH signaling pathway, there are identified isoforms of the GLI
proteins that function abnormally from their traditional counterparts. For example, GLI1 has an
isoform which lacks exons 2 and 3, leading to a truncated GLI1_ΔN form. This isoform has been
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described in healthy and malignant tissue showing no binding to SUFU (Shimokawa et al. 2008).
Another isoform, tGLI1, is only found in cancer cells like glioblastoma multiforme, and lacks
exons 3 and 4. It has increased motility and evasiveness, which is something a tumor could
capitalize on (Lo et al. 2009). GLI2 also shares a handful of isoforms, but there are no reports of
GLI3 isoforms in humans (Matissek and Elsawa 2020). Further investigation is required to
elucidate alternative roles for GLI3. Even so, these discoveries hint at a fuller role the GLIs
could play in regulating aspects of cancer growth and metastasis.

Non-canonical GLI activation
Novel, non-canonical roles for the GLI genes are gradually being unearthed across
multiple signaling pathways. There have been several instances describing a cross-talk between
the HH-GLI and RAS-RAF-MEK-ERK signaling pathways. For example, it was shown that a
constitutively active MEK1 increases GLI1 activity, and inhibiting MEK1/2 returns GLI1 to
normal levels (Riobo et al. 2006). Along the same vein, the authors identified a region of GLI1
responsible for sensing ERK1/2 signaling; and deleting this region yields an active GLI1 that is
no longer sensitive to MEK1 signaling. Within pancreatic ductal adenocarcinoma (PDAC), GLI1
is shown to control DNA mismatch repair (MMR) proteins. Normally, MMR recognizes
abnormalities in the genome such as double stranded breaks and quickly corrects these issues.
Despite this, MMR can fail to function, resulting in microsatellites and a faster DNA mutation
rate (Pecina-Slaus, et al. 2020). Both GLI1 and GLI2 activate a suppressor of the MMR protein
MLH1, and a double knockdown of the GLI proteins led to an increase of MLH1 in PDAC cells
(Inaguma, et al. 2013). In other words, GLI1 can disable MMR proteins, leading to mutations
that contribute to the progression of PDAC. In esophageal adenocarcinoma (EAC), GLI1 can be
5

phosphorylated by S6K1 in the TNFα/mTOR pathway (Wang, et al. 2013). After
phosphorylation, GLI1 acts as a potent oncogenic promoter, so it is beneficial to inhibit S6K1
activation.
GLI2 also has many instances of non-canonical activation and crosstalk with other
pathways. Studying an interaction described between TGF-β and HH-GLI signaling now
associates GLI proteins with cancer stem cells and chemoresistance. Interestingly, recurrent
ovarian tumors contain cancer stem cells that express high levels of GLI2 and components of the
TGF-β pathway. Inhibiting GLI2 makes the cells more susceptible to cisplatin treatment and
reduces their proliferation (Steg et al. 2012). In colorectal cancer, GLI2 is strongly induced by
TGF- β2 secreting cancer associated fibroblasts (Tang et al. 2018). This occurs independently of
HH signaling and promotes chemoresistance in colorectal cancers, increasing the chances of
relapse following chemotherapy. In gastric cancer tissues, a micro-RNA called miR-218 is
shown to negatively regulate GLI2 (Ruan, 2015). When miR-218 is upregulated, the cancer cells
have decreased levels of proliferation and invasion. Inversely, inhibiting miR-218 results in more
invasion and metastasis by the gastric cancer. This suggest that GLI2 is assisting the cancer
growth in some fashion. Additionally, increased levels of GLI2 positively correlate with growth
of medulloblastomas in the nervous system (Flora, et al. 2009). The transcription factor ATOH1
activates transcription of GLI2 which leads to development of neuron precursors, and mutations
in their cell cycle can lead to medulloblastoma formation. When deleting Atoh1 from a mouse
model, GLI2 is no longer activated, and cerebellar tumor formation is prevented. Focusing on
breast cancer metastasis, a complex interaction is described between the BCAR4 transcription
factor and GLI2 activation. BCAR4 is a long non-coding RNA (lncRNA) that is present in
advanced breast cancers with high rates of metastasis. CCL21 signaling causes BCAR4 to bind
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several transcription factors that ultimately relives inhibition of RNA polymerase II further
downstream in the pathway. In turn, a non-canonical HH/GLI2 transcription program is
activated, promoting cell migration (Xing, et al. 2014). More recently, GLI2 was demonstrated
as essential to the development of castration-resistance prostate cancer (CRPC). Knocking down
GLI2 in androgen-responsive prostate cancer cells resulted in a reduction in cell viability and a
reduction in genes associated with cell cycle progression (Xia, et al. 2020). Knocking down
GLI2 enhanced the effect of the antiandrogen drug Casodex and prevented further growth of
CRPC cells. Furthermore, the same effect was observed in a xenograft mouse model, confirming
this mechanism in vivo.

GLI3
While the first two GLI genes are well studied, GLI3 is less well-characterized. Despite
this, numerous studies seek to target GLI3 for cancer therapy due to its role in cancer progression
(Fernanda et al. 2018, Shen et al. 2021, Peng and Zhang 2021). Because of its importance as the
premier HH signaling pathway inhibitor, researchers continue to unearth new roles for GLI3,
elucidating its versatility throughout the body and enhancing our understanding of this very
important transcription factor.
In addition to the aberrant cancer cell growth and metastasis, GLI3 has been shown to
have a regulatory role during normal functioning of both the innate and adaptive immune
systems. During thymocyte development, GLI3 is differentially expressed between some of the
double negative (DN) stages of the adult thymocytes (Hager-Theodorides, et al. 2005). The same
study suggests that GLI3 is involved in transitioning the cells from CD4-CD8- DN cells to

7

CD4+CD8+ double positive (DP) cells. As a transcription factor, GLI3 could regulate genes that
control T-cell development in the thymus. GLI3 was also demonstrated to be necessary for B cell
development in the fetal liver (Solanki, et al. 2017). Mutating GLI3 led to a reduction in
progenitor B cell populations. Furthermore, mutated GLI3 caused lower expression of the master
transcriptional regulators of B cell differentiation: Pax5 and Ebf1. As observed, it seems that
GLI3 plays a broader role in cell development than originally thought, especially in the adaptive
immune system.
Understanding how GLI3 regulates inflammatory cytokine secretion in innate immune
cells would be significant because these are some of the first cells to infiltrate an area of
infection in the body. They lay the groundwork for an immune response and recruit more
specialized adaptive immune cells to the area by secreting pro-inflammatory cytokines and
chemokines (Navegantes et al. 2017).
In a genome-wide screen of LPS-induced genes in mouse macrophages, GLI3 was found
to be upregulated in response to LPS stimulation suggesting an interaction between GLI3 and the
TLR4 signaling pathway (Ravasi et al. 2002). Another study sought to further clarify interactions
between GLI3 and the TLR4 pathway, by inhibiting p38 and mutating the TRIF adaptor protein,
resulted in a lack of GLI3 induction by LPS (Boi et al. 2013). This suggests the TLR4-TRIF-p38
axis is relevant to GLI3 activation. As stated previously, LPS stimulation of TLR4 increases proinflammatory cytokines and chemokines such as CCL2 and CCL7. Recent studies show that
monocyte stimulation by LPS increased GLI3 mRNA and protein expression (Matissek and
Elsawa 2019). As a result, the inflammatory cytokines IL-6, TNF-a and CCL2 showed increased
expression. Furthermore, macrophages from mice with conditional knockout of Gli3 in myeloid
cells (M-Gli3-/-) stimulated with LPS had significantly reduced levels of IL-6 and CCL2
8

secretion compared to wild-type mice (Matissek and Elsawa 2019). Taken together, these studies
hint at a novel role for GLI3 in mediating TLR4-induced inflammation.
The pro-inflammatory cytokines activated in response to TLR stimulation cause a variety
of responses from the immune system in order to combat infection. For example, CCL2 is a
chemoattractant protein that drives chemotaxis of myeloid and lymphoid cells to an area of
infection (Gschwandtner et al. 2019). Under normal circumstances, CCL2 is also involved in
polarizing T cells into the T-helper 2 (Th2) phenotype and macrophages into an M1 or M2
phenotype (Deshman, et al. 2009, Ruytinx et al. 2018). M1 macrophages are a pro-inflammatory
cell subtype, indicating that CCL2 is a potent activator of the immune response. However, it is
necessary to acknowledge that CCL2 binds to its receptor, CCR2, to cause differentiation of cells
into appropriate phenotypes for the situation at hand (whether it be pro-inflammatory or antiinflammatory). Often, CCL2 is implicated in autoimmune diseases like rheumatoid arthritis
(RA), causing an influx of monocytes into the synovium between joints which results in
significant pain (Moadab et al. 2021). In the tumor microenvironment, CCL2 could help tumor
growth by inducing myeloid cell differentiation into tolerogenic dendritic cells (DC) and
increasing angiogenesis (Yang et al. 2020, Salcedo et al. 2000). As can be seen, CCL2 can
provide a variety of functions in the immune system, sometimes preferring to induce
inflammation and other times suppressing an immune response in conditions like cancer.
IL-6 is a pleiotropic cytokine that has been shown to promote inflammation. Its
multifunctionality includes stimulating B-cell differentiation, production of acute phase proteins
(APPs), synthesis and secretion of immunoglobulins, among others (Hirano et al. 1985, Tanaka
et al. 2014, Takatsuki et al. 1988). Activating the acute phase response by stimulating production
of APPs is paramount to mounting an immune response against invading pathogens.
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Demonstrating that IL-6 is necessary for antibody production further solidifies it as a premier
pro-inflammatory cytokine (Takatsuki et al. 1988). Having these roles mark the significance of
IL-6 as an activator of the immune response; however, its other functions cannot be understated.
A combination of IL-1 and IL-6 can differentiate T cells into natural killer (NK) cells (Luger et
al. 1989). These NK cells play a major role in recognizing virally infected cells and cancer cells,
triggering cytotoxicity. IL-6 initiates three main signaling pathways: JAK/STAT3, Ras/MAPK,
and PI3K/Akt (Kaur et al. 2020). Together, these pathways regulate many aspects of cell
proliferation, differentiation, apoptosis, angiogenesis, and metastasis in multiple cancers. As IL-6
is the major cytokine in the tumor microenvironment, its deregulation can lead to a myriad of
problems including tumor cell growth and survival. Similar to CCL2, IL-6 is also elevated in
some autoimmune diseases such as RA and Castleman disease, a disorder characterized by
overgrowth of cells in the lymph nodes (Chung et al. 2011, Yoshizaki et al. 2018). As can be
seen, IL-6 function is well characterized and widely explained across multiple signaling
pathways and multiple diseases.
A third important inflammatory cytokine is tumor necrosis factor alpha (TNFα). As its
name suggests, this protein activates cell signaling pathways that will lead to death via necrosis
or apoptosis of infected cells and cancers (Idris and Naismith 2000). There are two main
receptors for TNFα: TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) (Locksley et al.
2001). TNFR1 is expressed on all cells, activating inflammation and tissue degeneration upon
TNFα binding (Grell et al. 1995). On the other hand, TNFR2 is only expressed on certain cell
types such as immune cells and endothelial cells. TNFR2 doesn’t have a death domain, so it’s
proposed that TNFα binding to TNFR2 mediates local cell survival and tissue regeneration
(Probert 2015). An interesting aspect of TNFα that has been discovered is its ability to prime
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cells, enhancing their inflammatory response. A small amount of TNFα is enough to prime
fibroblast-like synoviocytes (FLS) in RA patients so that they respond to suboptimal levels of
interferons (Sohn et al. 2015). Of course, TNFα activates genes differently in different cell types.
For example, TNFα abundantly induces IL-6 in FLS, but macrophages produce IL-6 in response
to TNFα in a lower and more transient amount (Lee et al. 2013). This statement also shows how
multiple transcription factors interact with each other to modulate the secretion of other
inflammatory cytokines. Taken together, IL-6, CCL2, and TNFα are important molecules to
consider when studying the role of Gli3 in modulating inflammatory cytokine secretion by
monocytes.

Transcriptional regulation
Gene transcription is activated in multiple ways; one of those being acetylation. When an
acetyl group is attached to a lysine residue on the N-terminal tail of a histone core, the positive
charge on that residue is neutralized. This decreases the interaction between the negatively
charged DNA and the histone, resulting in a more relaxed DNA structure that is accessible for
gene transcription (Verdone et al. 2006). Histone acetyl transferases (HATs) are necessary for
the addition of this acetyl group, and one of the most common and best studied protein pairs are
the proteins p300 and CREB-binding protein (CBP). p300/CBP have diverse functions across
multiple cell types (Dancy and Cole 2015). Most importantly, their role in cell growth and
differentiation has been established (Sano et al. 1998, Kimura et al. 2005, Kalkhoven 2004). Part
of this could be due to one of the domains of p300 being able to recruit a range of transcription
factors such as p53, NF-κB, c-Jun, STAT1, among others (Karanam et al. 2007). It seems that
p300 interacts with these transcription factors to activate gene transcription. It is also important
11

to note that mutations in p300 can lead to cancer (Gayther et al. 2000). This suggests that it
functions as a tumor suppressor gene to instigate a pro-inflammatory immune response to help
clear cancer cells.
A study analyzing the KRAS oncogene and its role in the formation of autophagosomes
identifies a unique interaction that could be an important step towards understanding how GLI3
functions during inflammation. Expression of vacuole membrane protein 1 (VMP1) is essential
for autophagy, and this gene is conserved across many organisms (Vaccaro et al. 2008). The
KRAS oncogene was shown to require VMP1 to induce autophagy in cancer cells (Lo Ré et al.
2012). More importantly, these studies also showed that Gli3 binds to the VMP1 promoter to
regulate its activity. Furthermore, chromatin immunoprecipitation studies performed in this study
showed that p300 physically complexes with the GLI3 transcription factor to bind and modulate
the VMP1 promoter (Lo Ré et al. 2012). It is unknown how exactly this intriguing interaction
takes place and what is required for p300 to complex with Gli3. However, there are two potential
acetylation sites on Gli3, located on the c-terminal side of the zinc-finger domain
(PhosphositePlus.org). It is possible that in some instances p300 may acetylate Gli3, allowing it
to regulate gene transcription. Therefore, further investigation is necessary in order to determine
if p300 and Gli3 work in tandem to modulate gene transcription, especially in the context of proinflammatory cytokine expression in human monocytes.

Identifying novel protein interactions
Proximity labeling is an excellent technique to study transient and lasting interactions
between proteins in cells. It would also allow our lab to identify novel GLI3 binding partners and
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push our research in new directions. Escherichia coli contains a biotin ligase called BirA which
regulates enzyme activity of acetyl-CoA carboxylase by biotinylating it. This is achieved by
BirA binding biotin and ATP to generate a bioAMP intermediate, which BirA can then transfer
to the enzyme (Lin, et al., 2017). A simple amino-acid substitution (R118G) dramatically
increases the bioAMP dissociation rate, so BirA can be used to label all proximal proteins
instead of just the specific enzyme it would normally bind (Mair, et al., 2019). TurboID is an
engineered biotin ligase that further refines this proximity labeling technique. TurboID has
higher activity than its precursor, BioID, enabling higher sensitivity, greater activity, lower
temperature requirement, and a broader application in vivo (Mair, et al., 2019). This technology
could be useful for identifying novel proteins that GLI3 interacts with.
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MATERIALS AND METHODS
Cell Culture
Human monocyte cell lines MM6 (DSMZ), THP-1 (ATCC), and U937 (ATCC) were
sub-cultured in tissue-culture treated flasks under a biosafety cabinet. RPMI-1640 media was
used to grow and maintain all three cell lines (Gibco). For MM6, RPMI was supplemented with
10% heat inactivated fetal bovine serum (Gibco), 1% antibiotic-antimycotic (Gibco), 1% sodium
pyruvate (Cellgro), and 1.25 mL recombinant human insulin (Gibco). For THP-1, RPMI was
supplemented with 10% FBS, 1% AA, and 1% L-glutamine (Corning). For U937 RPMI was
supplemented with 10% FBS and 1% AA. The cells were passaged every 3 days or when they
reached confluency.

Antibodies and reagents
Rabbit anti-human p300 mAb (D2X6N) was purchased from Cell Signaling technology.
Rabbit anti-human GLI3 pAb (ab123495) was purchased from Abcam. Goat anti-human/mouse
GLI3 (AF3690) and goat anti-human (BAF3690) were purchased from R&D Systems. Rabbit
anti-goat HRP-conjugated secondary antibody (31402) purchased from ThermoScientific (Pierce
Antibody). Donkey anti-rabbit HRP-conjugated secondary antibody (NA934V) purchased from
GE Healthcare UK Limited.
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Electroporation Transfection
Cells were resuspended in Opti-MEM (Gibco) at 1*10^6 cells/ 100 µL. Cells were
combined with plasmid vectors in generic cuvettes and then transfected with ECM 830
Electroporator at varying 1-pulse conditions. MM6 was electroporated at 250 V for 25 ms. THP1 was electroporated at 250 V for 25 ms. U937 was electroporated at 300 V for 10 ms. Cells
were left to rest in cuvettes 15 minutes after electroporation and before media was added and
plating.

Immunoprecipitation
Monocytes (4*106 cells) were transfected with either an empty plasmid vector (EV) or a
p300 expression plasmid vector and plated in 6-well plates with 2 mL media. After 48 hrs, cells
were harvested and spun at 1.2 x g for 5 min to pellet cells. Supernatant was discarded and cells
were washed in PBS, then centrifuged again. 500 µL lysis buffer (Pierce IP kit) was added to
each pellet, and lysates were incubated on ice with periodic mixing for 5 min. Cell debris was
removed by centrifugation at 13,000 x g for 10 min. Protein concentration was measured using
Pierce bicinchoninic acid (BCA) protein assay kit.
Immune complex was prepared by combining 250 µg cell lysate with 1:200 dilution of
rabbit anti-p300 monoclonal antibody (Cell Signaling: D2X6N). Simultaneously, a negative
control was prepared with 1:200 dilution rabbit IgG isotype control (Novus: NBP2-36463).
Antibody/lysate solution was diluted to 500 µL with IP lysis/wash buffer. Solution was
incubated overnight at 4℃ with mixing to form immune complex. A manual
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immunoprecipitation was performed following the steps outlined in the Pierce classic magnetic
IP/Co-IP Kit. Samples were run on western blot to view protein expression.

Western Blot
Cell extracts were lysed in 100 µL RIPA buffer (Pierce) containing protease inhibitor
(Pierce). Cell lysate was sonicated to facilitate lysing and shear genomic DNA. BCA assay was
used to determine the protein concentration and adjust all samples to the lowest value. Samples
were diluted in 5X loading dye with 3.5% β-mercaptoethanol. The sample/loading dye mixture
was heated at 98℃ for 5 min and briefly spun down before being loaded in a 5% gel. The gel
was run at 100 V for 15 min and then 130 V for 1 hr. Proteins on the gel were transferred to a
nitrocellulose membrane using the semi-dry Trans-Blot Turbo (Bio-Rad) for 30 min at 25 V. The
membrane was blocked with Everyblot blocking buffer (Bio-Rad) for 5 min. Next, the
membrane was washed with 1X tris buffered saline with .01% tween 20 (TBST) for 10 min. The
membrane was soaked with a 1:1000 dilution of the primary antibody overnight with rocking at
4℃. The membrane was washed with TBST for 5 min, 3 times. A 1:10,000 dilution of the
secondary antibody was added to the membrane for 1 hr with shaking. The membrane was
washed with TBST for 5 min, 2 times, and it was washed a final time with TBS for 5 min. 1 mL
of a 1:1 solution of luminol/enhancer and stable peroxide was spread across the surface of the
membrane (SuperSignal West Dura Extended Duration Substrate). The membrane was imaged
and developed with X-ray film or the Chemidoc Gel imaging system (BioRad).
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Single/Dual Luciferase Reporter Assays
U937 cells (4*10^6 cells) were transfected with 4µg CCL2p_pGL4.10 [luc2], 2ng
Renilla plasmid (pGL4.70 [hRluc]) for dual luciferase (DLR), and 4µg GLI3-HisC, 4µg Flag
3X-p300 overexpression plasmids, or empty vector. For a DLR knockdown, 7 µg scrambled
shRNA (shScr), shGLI3, or shp300 was used for transfection. After 48 hrs, the cells were
harvested and lysed in 1x passive lysis buffer (Promega). Cells were lysed on ice for 5 min with
occasional mixing. Lysate was spun down at 10,000xg for 10 min. 20 µL of sample was loaded
in triplicates onto half-area 96-well plates and the plate was inserted into the Berthold Centro LB
960XS luminometer. The luminometer injected 50 µL luciferase assay substrate (Promega) and
50 µL Stop and Glo buffer (Promega), reading each for 10 seconds. Output is measured in
relative luminescence units (RLU), which represent a ratio of firefly to renilla luciferase activity.

Transformation
Chemically competent DH5α cells (Invitrogen) were thawed on ice and transferred to
new tubes in 25 mL aliquots. 1 µL DNA was added for each transformation and cells were
gently mixed. Tubes were incubated on ice for 30 min. Cells were heat shocked for 20 s at 42℃,
and then cells recovered on ice for 2 min. 950 µL 2x LB Broth (Thermo Fischer) was added to
each transformation, and tubes incubated at 37℃ for 1 hr at 300 rpm. Then, 100 µL of the
transformation was spread on its antibiotic specific plates (Ampicillin from Sigma). Plates were
incubated overnight at 37℃.
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Plasmid purification
One colony was chosen to create a starter culture in 5 mL LB with antibiotic for 8 hrs. 1
mL of starter culture was added to 1 L sterile LB with antibiotics and grew for 15-18 hrs at 37℃
and 200 rpm. Cultures were transferred to large centrifuge bottles (750 mL each) and centrifuged
at 4,000xg for 30 min and 4℃. Supernatant was decanted before following plasmid purification
protocols from Qiagen. Maxiprep columns were washed with 150 mL sterile water and
equilibrated with 35 mL buffer QBT. The bacteria pellet was resuspended in 10 mL buffer P1
and transferred to a 50 mL tube. Bacteria cells were lysed with 10 mL buffer P2 and mixed
immediately. Lysis suspension was neutralized with 10 mL buffer P3. Tubes incubated on ice for
20 min with 20 inversions every 5 min. Solution was centrifuged at 4,000xg for 30 min at 4℃.
After centrifuging, supernatant was separated from precipitate and applied to the column to flow
through. 200 mL buffer QC was used to wash the column. Plasmid DNA was eluted with 30 mL
buffer QF. 20 mL isopropanol was added to DNA and tube was inverted. Tube was centrifuged
at 4,000xg for 30 min at 4℃. Supernatant was decanted and DNA pellet was washed with 5 mL
80% ethanol before being centrifuged again for 10 min. Supernatant was decanted and pellet was
left to air dry before measuring DNA concentration.

Quantitative real-time PCR (qPCR)
Total RNA was extracted from cells using 1 mL Trisure (Meridian Bioscience) following
manufacturer recommendations. 200 µL chloroform was added to each sample, vortexed until a
slush, and incubated at room temperature for 5 min. Samples were spun at ~12,000xg for 15 min
at 4℃. After, the top layer was pipetted into a new tube. 500 µL isopropanol was added to each
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sample, thoroughly mixed by inversion, and incubated at room temperature for 10 min. Tubes
were spun at ~12,000xg for 15 min at 4℃. Supernatant was discarded, and the pellet was washed
with 1 mL 75% ethanol. Tubes were spun again at ~12,000xg for 5 min at 4℃. Supernatant was
discarded, and the RNA pellet was air dried before resuspending in 20 µL nanopure water.
RNA samples were heated at 65℃ for 15 min and then concentrations were measured.
Sample concentrations were adjusted to 5000 ng/µL or the lowest sample concentration if
necessary, using nanopure water. For each sample, RNA and nuclease free water was added to a
volume of 12 µL alongside 1µL each of dNTPs (Invitrogen) and random decamers (IDT).
Reaction was heated to 65℃ before adding 4µL 5x M-MLV buffer (Promega), 1µL nucleasefree water, and 1µL M-MLV reverse transcriptase (Promega) to each reaction. A reverse
transcription program was run on a thermal cycler to complete reaction, and cDNA was diluted
with 20 µL nuclease-free water for use with qPCR.
Primer sequences employed for PCR amplification are as follows: GAPDH, forward, 5’ACC ATC TTC CAG GAG CGA GAT-3’; reverse, 5’- ATG ACG AAC ATG GGG GCA TC3’; GLI3, forward, 5’- GGG ACC AAA TGG ATG GAG CA-3’; reverse, 5’- TGG ACT GTG
TGC CAT TTC CT-3’; p300, forward, 5’- TTC AAA CGC CGA GTC TTC TT-3’; reverse, 5’GTT GAG CTG CTG TTG GCA TA-3’; IL-6, forward, 5’- TCC AAA GAT GTA GCC GCC C3’; reverse, 5’- CAG TGC CTC TTT GCT GCT TTC-3’; CCL2, forward, 5’- GCC ACC TTC
ATT CCC CAA GGG-3’; reverse, 5’- GCT TCT TTG GGA CAC TTG CTG C-3’; TNFα,
forward, 5’- CCA GGG ACC TCT CTC TAA TCA-3’; reverse, 5’- TCA GCT TGA GGG TTT
GCT AC-3’. qPCR was done with PR1Ma qMax Green Hgh Rox qPCR Master mix (PR1MA)
and run on Applied Biosystem’s AB-ViiA7 real-time PCR system. Data was analyzed with
Microsoft Excel and GraphPad Prism. Real-time cycle conditions were 20s at 95℃ then 40
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cycles of 95℃ for 15s and 60℃ for 1 min. GAPDH was used as an internal control and relative
fold changes were calculated based on 2-ΔCt method.

Cloning
The pcDNA3.1/His C-GLI3 plasmid containing the GLI3 coding sequence was used to
isolate GLI3. A forward primer (5’-gccggcATGGAGGCCCAGTCCCACAG-3’) and a reverse
primer (5’-gaattcCTATTGCATAACTGCAAGG-3’) were used to amplify the GLI3 gene from
the plasmid. The primers contained the EcoRI and NaeI restriction sites accordingly on their 5’
ends. Primers were reconstituted at .25 mg/mL in ultrapure water. PCR reaction consisted of:
2.5 µg template DNA (GLI3-HisC), 20µL ultrapure water, 1.25µL forward primer, 1.25µL
reverse primer, and 25 µL Emerald Amp GT PCR Master Mix (Takara).
PCR was performed using a Mastercycler pro S (Eppendorf) at 94℃ for 1 min; 40 cycles
at 94℃ for 15 seconds, 57℃ for 30 seconds, 72℃ for 100 seconds; and 72℃ for 7 minutes. A
1% agarose gel was prepared (MidSci) in 1X TAE buffer, and 0.01% SYBR Safe DNA gel stain
(Invitrogen) was added to the solution. The PCR product was loaded on the agarose gel at 100V
for 1 hour in 1X TAE Buffer. The separated DNA fragments were visualized using a Gel Doc™
XR+ (BIO-RAD) and analyzed by Image Lab™ software (BIO-RAD) and quickly cut to
minimize the UV exposure. DNA was extracted from the gel slice using GeneJET Gel Extraction
and DNA Cleanup Micro Kit (Thermo Scientific). The concentration of DNA was determined
using a nanodrop spectrophotometer.
Digestion was accomplished in a single step but separate tubes for the GLI3 and TurboID
DNA samples. The digestion reaction consisted of: 1µL (10 units) NaeI restriction enzyme (RE)
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(NEB), 1µL (20 units) EcoRI-HF RE (NEB), 5 µL 10x rCutsmart Buffer (NEB), either 1µg
TurboID DNA or 511 ng GLI3 DNA, and nuclease free water up to 50µL total reaction volume.
Digestion reactions were incubated overnight at 37℃. DNA was purified using PureLink Quick
PCR Purification Kit (Invitrogen), and concentration was again measured with the nanodrop
spectrophotometer.
The NEBiocalculator was used to calculate molar ratio of insert:vector (3:1) necessary for
the ligation reaction. The GLI3 insert is 4,743 bp and TurboID plasmid is 7,603 bp. The ligation
reaction consisted of: 2 µL T4 DNA ligase buffer (10x) (NEB), 50 ng vector DNA, 93.57 ng
insert DNA, 1µL T4 DNA ligase (NEB), and nuclease free water up to 20 µL total reaction
volume. The ligation reaction was incubated at 16℃ overnight. Then, it was heat inactivated at
65℃ for 10 minutes and left to chill on ice for transformation.
Transformed bacteria was miniprepped following protocol by GeneJET plasmid miniprep kit (Thermo Scientific). Cultures were grown in 3 mL for 24 hours. Cultures were spun
down at 4,000xg for 5 min at 4℃ and supernatant was poured off. Pellet was resuspended in 250
µL resuspension solution (RNAse A added) and transferred to a microcentrifuge tube. 250 µL
lysis solution was added and mixed by inversion 5 times. 350 µL neutralization solution was
added a mixed by inversion 5 times. Tubes were centrifuged for 5 min at 12,000xg to pellet.
Supernatant was transferred to a GeneJET spin column and centrifuged for 1 min. Flow through
was discarded. 500 µL wash solution was added and tube was centrifuged for 1 min at 12,000xg.
Flow through was discarded and wash step was performed again. Tube was centrifuged again
with no wash solution to remove residual ethanol. The column was transferred to a new 1.5 mL
microcentrifuge tube, and 50 µL of elution buffer was added to the center of the column. Tube
was incubated at room temperature for 2 min before centrifuging at 12,000xg for 2 min.
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Miniprepped DNA from the transformation colonies was checked for successful cloning
by another digestion reaction as previously described or it was checked by PCR screening. To
PCR screen, a piece of the colony was scooped and swirled into 10 µL ultrapure water to use as a
DNA template. The PCR was carried out as previously described to amplify for GLI3.

Statistical Analysis
All values in the figures are presented as mean + standard error of the mean with n ≥ 3
independent observations. Statistical analyses were performed using Student’s t test or multiple
comparisons ANOVA with GraphPad Prism (GraphPad Software, Inc Version 9.3.1) A P-value
<0.05 was considered statistically significant.
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RESULTS
GLI3 and p300 Physically Interact in Human Monocytes
Previous studies have shown that GLI3 and the acetyltransferase protein p300 interact to
regulate gene expression in cancer cells (Lo Ré et al. 2012). Therefore, the first aim of my
project was to determine if GLI3 and p300 interact in monocytes to modulate inflammatory
cytokine expression and secretion. These experiments were performed across multiple human
monocyte cell lines: MM6, THP-1, and U937. To start investigating this, I performed coimmunoprecipitation studies to determine if these two proteins form a physical complex in innate
immune cells. The human monocyte cell line U937 was transfected with either an empty vector
(pCMV14-3xFLAG), or a p300 overexpression construct (pCMV14-3xFLAG p300). After 2
days, cells were lysed and analyzed by western blot to determine protein expression. I was
unable to identify full-length GLI3 protein (190 kDa). Immunoprecipitating p300 and western
blotting for GLI3, showed an interaction (Figure 1). Additional antibodies designed to recognize
human GLI3 were tested to see if a clearer band could be discerned and to further confirm the
interaction between the two proteins. However, none of the antibodies tested yielded GLI3 at the
expected 190 KDa size (Figure 2).

23

p300 OE

GLI3 OE

Both OE
IP: p300
WB: GLI3
Figure 1: IP study shows interaction between p300 and GLI3. P300 was immunoprecipitated out
of solution and western blot was performed for GLI3 with R&D AF3690 antibody (designed to
recognize human and mouse GLI3). Lane 1 contains input from purified lysate. Lane 2 contains
IP of IgG control. Lane 3 contains the p300 IP pulldown. Cells were transfected with
overexpression construct for p300, GLI3, or both.
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THP-1
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IP
p300

Figure 2: IP with additional Gli3 antibody shows interaction between GLI3R and p300. Band for
Lane 1 contains BioRad Precision Plus Protein Standard with labeled ladder marks. Lane 2 is
lysate from U937 cells. Lane 3 is lysate from THP-1 cells. Lane 4 is the protein sample isolated
from THP-1 cells and immunoprecipitated for p300. The red arrow indicates the band
representing GLI3R in the IP sample.
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Inflammatory Cytokine mRNA Expression is Modulated by GLI3 and p300
After confirming the presence of a physical interaction between GLI3 and p300 in
monocytes, I wanted to see how this interaction affected the expression of key inflammatory
cytokines. To address this, I studied the effect of GLI3 and p300 on the mRNA expression of the
cytokines IL-6, CCL2, and TNFα using qPCR. I overexpressed GLI3, p300 or both in monocyte
cell lines and examined gene expression after 48 hours. Figure 3 shows the successful
upregulation of GLI3 and p300 in monocyte cell lines. Both GLI3 and p300 were significantly
upregulated as a result of transfecting with a GLI3 and p300 overexpression plasmid
respectively. An empty vector plasmid was transfected into monocytes as a control. Using MM6
cells, p300 seems to have a positive induction of IL-6 expression, but the combination of p300
and GLI3 also shows an increase in IL-6 expression (Figure 4). Similarly, p300 induces an
increase in the expression of CCL2 in the MM6 cells, but the combination overexpression does
not result in the same CCL2 increase. TNFα expression seems to increase in all overexpression
treatments, but statistical analysis deem this increase insignificant.
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Figure 3: qPCR controls for GLI3 and p300 overexpression. GLI3 expression is shown on the
left graph and p300 expression is shown on the right graph. Both are relative to a GAPDH
housekeeping control. An unpaired t-test was performed to determine significance.

Figure 4: Overexpression of relative cytokine expression obtained from qPCR run with cDNA
synthesized from MM6 RNA. Expression is calculated relative to GAPDH housekeeping control.
Data is analyzed with two-way ANOVA where significance is indicated by asterisks. Each data
set is comprised of a minimum of three independent runs.
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The results from the THP-1 cells were very supportive of the hypothesis. In all three
tested inflammatory cytokines, there was significantly higher expression for the combination
overexpression treatments (Figure 5). In addition, there seemed to be a stepwise increase in
relative cytokine expression from control to p300 overexpression, from p300 to GLI3
overexpression, and from GLI3 to the combination overexpression. An additive effect rather than
a synergistic effect is observed.

Figure 5: Overexpression of relative cytokine expression obtained from qPCR run with cDNA
synthesized from THP-1 cells. Expression is calculated relative to GAPDH housekeeping
control. Data is analyzed with two-way ANOVA where significance is indicated by asterisks.
Each data set is comprised of a minimum of three independent runs.
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Lastly, the U937 cells show that GLI3 is mainly involved in upregulating the expression
of inflammatory cytokines (Figure 6). In all three cytokines, GLI3 overexpression by itself
results in the highest expression values of the target cytokines. IL-6 expression is also
significantly upregulated in the combination overexpression with p300. The qPCR results from
this overexpression study show different stories in the three separate human monocyte cell lines.
Taken together, these results suggest that inflammatory cytokine expression correlates with
expression of Gli3/p300, warranting further investigation into the mechanism by which
Gli3/p300 regulate the expression of target inflammatory cytokines in monocytes.

Figure 6: Overexpression of relative cytokine expression obtained from qPCR run with cDNA
synthesized from U937 cells. Expression is calculated relative to GAPDH housekeeping control.
Data is analyzed with two-way ANOVA where significance is indicated by asterisks. Each data
set is comprised of a minimum of three independent runs.
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Knockdown experiments were also performed to test mRNA expression levels of
inflammatory cytokines. Monocyte cell lines were transfected with a scrambled short-hairpin
RNA (scr shRNA), shGLI3, shp300, or both shGLI3 and shp300 together. IL-6, CCL2, and
TNFα expression levels were measured using qPCR 48 hours post-transfection. Confirmation of
GLI3 and p300 knockdown can be seen in figure 7. Both GLI3 and p300 were downregulated by
their respective shRNA, but neither decrease was significant by the t-test. For MM6 cells, all
three treatments resulted in a significant decrease of IL-6 expression, though the combination
knockdown was not significantly different from either shGLI3 or shp300 treatment alone (Figure
8). Both shp300 and the combination knockdown resulted in a significant downregulation of
CCL2, but shGLI3 did not. All three treatments were also successful at downregulating TNFα
expression in MM6 cells. Also, the largest decrease in TNFα expression was found in
combination knockdown, which was less than either shGLI3 or shp300.

30

Figure 7: qPCR controls for shGLI3 and shp300. shGLI3 expression is shown on the left graph
and shp300 expression is shown on the right graph. Both are relative to a GAPDH housekeeping
control. An unpaired t-test was performed to determine significance.

Figure 8: Knockdown of relative cytokine expression obtained from qPCR run with cDNA
synthesized from MM6 cells. Expression is calculated relative to GAPDH housekeeping control.
Data is analyzed with two-way ANOVA where significance is indicated by asterisks. Each data
set is comprised of a minimum of three independent runs.
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The THP-1 knockdowns were not supportive of the hypothesis (Figure 9). TNFα was the
only cytokine that had any treatment result in a significant knockdown; p300 is shown to
downregulate TNFα expression in the THP-1 cells. Otherwise, the treatments resulted in
upregulated expression. Notably, the error bars on some treatments are very large.

Figure 9: Knockdown of relative cytokine expression obtained from qPCR run with cDNA
synthesized from THP-1 cells. Expression is calculated relative to GAPDH housekeeping
control. Data is analyzed with two-way ANOVA where significance is indicated by asterisks.
Each data set is comprised of a minimum of three independent runs.
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For the U937 cells, there was only a downregulation of CCL2 expression in the
combination knockdown (Figure 10). There also seems to be a downregulation of TNFα, though
it is not significant. Single knockdown with either shp300 or shGLI3 did not result in
downregulation of any cytokine, but the combination knockdown of all three cytokines was
decreased compared to the single knockdown.

Figure 10: Knockdown of relative cytokine expression obtained from qPCR run with cDNA
synthesized from U937 cells. Expression is calculated relative to GAPDH housekeeping control.
Data is analyzed with two-way ANOVA where significance is indicated by asterisks. Each data
set is comprised of a minimum of three independent runs.
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CCL2 Promoter is Activated in the Presence of GLI3 and p300
Bioinformatic analysis of the CCL2 promoter identified several candidate GLI binding
sites, suggesting that GLI3 may bind the CCL2 promoter to regulate its expression. To further
characterize the mechanism by which GLI3/p300 regulate CCL2 expression, we used a
luciferase reporter construct (pGL4.10) with the CCL2 promoter (pCCL2) cloned upstream of
the luciferase reporter gene. I transfected monocyte cells with pCCL2 and either GLI3
expression construct, p300 expression construct, both or empty vectors and examined luciferase
activity after 48 hours. Renilla was used as a control for luciferase activity, so the data is
represented as a ratio of firefly to renilla (Figure 11). The MM6 cells showed an increase in
firefly:renilla for GLI3 and combination overexpression in relation to the empty vector control.
The combination overexpression shows the highest promoter activation in MM6. In the THP-1
cells, no significant change is observed between any treatments. In the U937s, there is a
significant increase in firefly:renilla for the combination overexpression. The GLI3
overexpression treatment in U937 resulted in a lower firefly:renilla than the empty vector
control.
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Figure 11: Overexpression dual luciferase readings show promoter activation as a ratio of firefly
luciferase to renilla luciferase. Left to right are cell lines MM6, THP-1, and U937. Data is
analyzed with two-way ANOVA where significance is indicated by asterisks. Each data set is
comprised of a minimum of three independent runs.
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A dual luciferase study was also performed using RNAi to knockdown GLI3, p300 or
both using the same methods. I transfected monocyte cell lines with pCCL2 and either short
hairpin RNA targeting GLI3 (shGLI3), p300 (shp300), both, or a non-specific short hairpin RNA
scrambled sequence (shScr) and examined dual luciferase activity after 48 hours. For all three
cell lines, there was no significant decrease in firefly:renilla (Figure 12). In the U937s, luciferase
activity increased in the shp300 and combination knockdown treatments.

Figure 12: Knockdown dual luciferase readings show promoter activation as a ratio of firefly
luciferase to renilla luciferase. Left to right are cell lines MM6, THP-1, and U937. Data is
analyzed with two-way ANOVA where significance is indicated by asterisks. Each data set is
comprised of a minimum of three independent runs.
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CCL2 Cytokine Secretion is Modulated by GLI3 and p300
Next, the protein secretion of the cytokine CCL2 was quantified using an ELISA. Cells
were transfected with a GLI3 expression construct, a p300 expression construct or both and
compared to cells transfected with empty vector. Supernatants were diluted at 1:200 due to high
secretion levels of the cytokine. Then, a capture antibody was used to bind the sample, and a
detection antibody was used to visualize the binding via HRP substrate that caused a color
change. The absorbance was measured with a plate reader. All three treatments resulted in a
significant increase in CCL2 secretion (Figure 13). The combination expression resulted in more
CCL2 secretion than the sole overexpression of either GLI3 or p300. A similar trend is seen in
the THP-1 cells. The combination overexpression results in a larger CCL2 concentration,

however, none of the comparisons are significant.
Figure 13: Overexpression ELISA data represented as CCL2 concentrations in pg/mL. The left
graph is from U937, and the right graph is from THP-1 cells. Data generated as an average of
three independent experiments.
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I also transfected cells with shGLI3, shp300, both, or shScr plasmids. The ELISA data
show that GLI3 knockdown decreased CCL2 secretion in U937s but the p300 knockdown
actually increased CCL2 secretion (Figure 14). The combined knockdown of GLI3 and p300 had
no change relative to the control. In THP-1 cells, knockdown of GLI3 and the combined
knockdown of GLI3 and p300 decreased CCL2 secretion, though the decrease caused by GLI3
knockdown was not significant. The combined knockdown had the largest decrease in CCL2
secretion. The p300 knockdown resulted in an increase of CCL2 secretion.

Figure 14: Knockdown ELISA data represented as CCL2 concentrations in pg/mL. The left
graph is from U937, and the right graph is from THP-1 cells. Data generated as an average of
three independent experiments.
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Cloning GLI3 into TurboID
The second aim of my project was to develop techniques with TurboID proximity
labeling technology to identify novel GLI3 binding partners for future studies. To approach this,
I attempted to clone the GLI3 coding sequence into 3xHA-TurboID pRetrox (Figure 15).

Figure 15: Plasmid map of 3xHA-TurboID pRetrox. The cloning site is located between the NaeI
and EcoRI restriction sites on the 3’ end of the TurboID sequence. Figure obtained from
addgene.org.
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Primers were designed for the GLI3 sequence and contained the appropriate restriction
sites on the end of their sequence. Forward primer: 5’ GGTCTATGGGAAGTTCGGGG 3’.
Reverse primer: 3’ GGTCACAAGCACACCAACTCC 5’. After attempting to isolate GLI3 from
numerous sources, I was finally able to amplify GLI3 from a plasmid in our lab, GLI3 HisC
(Figure 16).

5kb

Figure 16: Gel electrophoresis of PCR product amplifying GLI3 from GLI3 HisC. Lane 1
contains the NEB 1 kb plus ladder. Bright bands indicated by the red arrow in lanes 2 and 3 are
at the expected size of 4,743bp. The band sits between 4,000bp and 5,000bp ladder markers. Gel
was run for 1 hour at 100V.
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Then, both the TurboID plasmid and the newly amplified GLI3 sequence were digested
with EcoRI and NaeI restriction enzymes in a single digestion reaction to generate sticky ends.
Figure 17 shows cut and uncut version of TurboID. The digested TurboID shows a band at 7,603
bp, the size of the plasmid. Both uncut and cut samples contain multiple bands, some higher in
size than what is expected of TurboID.

7kb

Uncut

Cut

Figure 17: Gel electrophoresis of purified digestion product. Lane 1 contains the NEB 1 kb plus
ladder. Lane 2 contains 100 ng of uncut TurboID in its plasmid form. Lane 3 contains 110 ng of
digested, linearized TurboID plasmid. The red arrow points to the band of TurboID.

41

Afterwards, the digestion reactions were purified, and ligation was carried out to insert
the GLI3 sequence into TurboID. The ligation product was transformed into competent E. coli
cells. There was not very much bacterial growth as a result of the transformations. The few
cultures that did grow were miniprepped and I isolated their DNA. To check if the ligation was
successful, I tried a variety of approaches. I first tried to PCR amplify GLI3 from the isolated
DNA (Figure 18). None of the colonies that I PCR screened seemed to have the GLI3 sequence
at 4.7 kb.
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Figure 18: Gel electrophoresis for PCR amplification of GLI3. Lane 1 contains NEB 1 kb plus
ladder. Lanes 2-9 contain DNA samples from different colonies that were PCR amplified for
GLI3. Lane 10 is the GLI3 HisC plasmid as a positive control.

I also performed digest screenings of the colonies by digesting with NaeI and EcoRI to
separate the insert from the plasmid and then running the DNA on a gel. I expected to see a band
at about 7.6 kb for the plasmid and another band at about 4.7 kb for the insert. However, I only
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ever observed bands for the plasmid at 7.6 kb and bands which indicated a larger piece of DNA
than I expected (Figure 19). GLI3 never showed up on the gel in any sample.
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Figure 19: Gel electrophoresis of digested DNA from colonies transformed with ligation product.
Lane 1 contains NEB 1 kb plus ladder. Lanes 2-9 contain DNA samples from the colonies that
were digested with restriction enzymes EcoRI and NaeI.
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I found that digesting my PCR amplified GLI3 with NaeI resulted in multiple smaller
bands as opposed to a single larger band (Figure 20). Both bands were around 2.3 kb which
could add up to the total size of GLI3.

5kb
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GLI3
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Figure 20: Gel electrophoresis of GLI3 shows NaeI cuts in middle of sequence. Lane 1 contains
NEB 1 kb plus ladder. Lane 2 is the GLI3 HisC plasmid (uncut). Lane 3 is the GLI3 sequence
amplified with cloning primers and cut with NaeI.
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HiFi Cloning Strategy
The next approach I attempted was HiFi cloning using the NEBuilder HiFi DNA
assembly cloning kit (NEB). I designed new HiFi primers that contain the restriction site for
NaeI and overlap of the TurboID plasmid. The HiFi cloning approach does not require digesting
the insert, so only digestion of TurboID with a single restriction enzyme is necessary. GLI3 was
still successfully amplified with the new HiFi primers (Figure 21).

5kb

Figure 21: Gel electrophoresis of PCR product amplifying GLI3 from GLI3 HisC with HiFi
Primers. Lane 1 contains the NEB 1 kb plus ladder. Bright bands indicated by the red arrow in
lane 2 are at the expected size of 4,743bp. The band sits between 5,000bp and 7000bp ladder
markers. Gel was run for 1 hour at 100V.
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I attempted to digest TurboID with both EcoRI and NaeI to see if one enzyme worked
better than the other. The restriction enzymes were successful at linearizing the plasmid as there
is a faint band that shows up at about 7.6 kb for TurboID (Figure 22). However, isolating the
DNA from the digestion reaction always resulted in a very low concentration, which is indicated
by the faint band. Also, there seem to be bands representing DNA that is larger than the expected
plasmid which can be seen at the top of the gel.

7kb
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NaeI Digest
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Figure 22: Gel electrophoresis of isolated DNA from TurboID digestion reactions. The left gel
contains TurboID digested with NaeI, and the right gel contains TurboID digested with EcoRI.
Lane 1 in both gels contains the NEB 1 kb plus ladder. Lane 2 and 3 on the left gel contain
TurboID digested with NaeI. A portion of lane 2 is removed from the right gel due to a high
concentration of another sample that was oversaturating the image. Lanes 3 and 4 on the right gel
contain TurboID digested with EcoRI. The red arrow indicates the TurboID band on the gel.
Other bands are unexpected products.
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Because the concentration of the digested TurboID was consistently low, it was difficult
to attempt ligation with GLI3. The few times I did attempt ligation with HiFi materials resulted
in few colony growths and no successful insertion of GLI3. I checked several colonies for the
insert by digesting miniprepped DNA with NaeI and was only able to visualize the TurboID size
at 7.6 kb and a larger, unidentified DNA band (Figure 23). GLI3 was not present on the gel.
Because of excess time and resources being dedicated to this aspect of my project, we decided to
have a company called VectorBuilder perform the cloning of GLI3 into TurboID.
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Figure 23: Gel electrophoresis of ligation products digested with NaeI. Lane 1 is NEB 1 kb plus
DNA ladder. Lanes 2-4 are different colonies that were miniprepped and digested to confirm the
presence of the GLI3 insert in TurboID. Bands are present at 7.6 kb, indicating the presence of
the plasmid, and a larger DNA fragment is also present.
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DISCUSSION
Evidence suggests that GLI3 and p300 physically interact in monocytes
The first aim of my project was to determine if GLI3 and p300 work together to modulate
pro-inflammatory cytokine expression and secretion. I sought to show a physical interaction by
performing an immunoprecipitation of p300 from human monocyte cell lines and then western
blotting for GLI3. Using multiple GLI3 antibodies, I was able to blot for a repressor form of
GLI3 at 83 kDa in the immunoprecipitation samples (Figures 1 & 2). This indicates that GLI3R
is physically interacting with p300 in the monocytes. However, the full length GLI3 protein was
not observed in the western blots. The western blot antibodies I used that were designed to bind
GLI3 are notoriously difficult to work with. This is one reason why I wanted to use multiple
antibodies to show an interaction. In figure 1, the bands are smeared and not crisp, so I chose to
pursue another antibody from Abcam which provides a much neater GLI3 band. It is imperative
to note that I only obtained the GLI3R band in figure 1 when both GLI3 and p300 were
overexpressed together in the cells. There are no visible GLI3R bands in either the sample with
GLI3 overexpression of p300 overexpression alone. In figure 2, the sample used to IP p300 was
also overexpressed with p300 in order to increase the chance of the antibody binding. It would be
interesting to see if an overexpression in either protein is necessary to visualize the interaction
between GLI3 and p300 or if they are already present at high enough amounts to observe the
interaction without overexpression.
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GLI3 and p300 Modulate Pro-inflammatory Cytokine Expression at the mRNA Level
A large portion of my experiments attempted to show that GLI3 and p300 worked in
tandem to modulate inflammatory cytokine production. I performed overexpression and
knockdown studies for GLI3 and p300 in three different cells lines: MM6, THP-1, and U937.
Then I performed qPCR experiments to measure mRNA expression of three proinflammatory
cytokines: IL-6, CCL2, and TNFα. The qPCR controls for GLI3 and p300 support that the genes
are indeed being overexpressed as a result of the plasmid being transfected (figure 3).
In MM6 cells, there is a significant increase in IL-6 expression when treating with both
GLI3 and p300 overexpression constructs, but CCL2 and TNFα are not significantly increased
by the same treatment (figure 4) However, p300 also causes a significant increase in IL-6
expression while GLI3 does not, so it could be said that p300, but not GLI3, increases IL-6
expression in MM6. TNFα does seem to be increased by the combination overexpression, but
statistics does not deem it significant. This could be due to excessive variation in betweenexperiment values, which results in a large standard error of the mean. For all three cytokines,
the p300 overexpression treatment alone increased their expression. Moreover, the increase
observed in IL-6 and CCL2 as a result of this treatment is significant. Overall, GLI3
overexpression alone does not seem to increase cytokine expression. Out of the two transcription
regulators, p300 could be the only one modulating these inflammatory cytokines’ secretion in
MM6.
Of course, it is necessary to test the same treatments in multiple cell lines to increase the
data’s validity. In THP-1, there is a significant increase in all three cytokines with the
combination overexpression treatment (figure 5). In fact, this increase is largest out of all the
treatments and highly supportive of the initial hypothesis. IL-6 expression in THP-1 is still
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significantly increased by the sole overexpression of GLI3 or p300, but this increase is not as
extravagant as the combination of them both. Therefore, p300 and GLI3 are observed to have an
additive effect for IL-6, CCL2, and TNFα expression in THP-1.
Lastly, in U937 cells, GLI3 overexpression is the dominant cause of increased expression
in all three cytokines (figure 6). In IL-6 especially, there is a marked increase in expression
between the GLI3 treatment and all other treatments. It is worth noting that the combination
overexpression results in a significant increase in IL-6 as well, but this pattern is not seen in the
other two cytokines. This could be due to the massive increase in IL-6 expression caused by
GLI3 overexpression alone.
There seems to be variation between cell lines in which treatment increases cytokine
expression the most. Even so, there are trends when viewing the data. There is never a
downregulation of cytokine expression as a result of the induced expression treatments. The
p300 or GLI3 overexpression alone will increase the cytokine expression, and the combination of
both of them sometimes results in an even larger increase. I’d like to point out the stepwise
increase of cytokine expression in the THP-1 cells starting from the empty vector control and
increasing up to the combination overexpression. This could hint at an additive effect that these
two transcription regulators have. When they are both present in high amounts, inflammatory
cytokine expression can be said to increase more so than if either is present without the other.
Though, this would need to be proven with further replicates of overexpression experiments and
further standardization of the cell lines (such as starting over with a fresh passage of cells). If
future studies are to be performed studying the interactions between overexpressing GLI3 and
p300 on cytokine expression, I would recommend using THP-1 monocytes.
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Accompanying knockdown qPCR experiments were also performed. Here a shRNA was
used to specifically knock down GLI3, p300, or neither with a scrambled shRNA. The qPCR
knockdown controls did show a decrease in GLI3 and p300 expression as a result of transfection
with the shRNAs, but a t-test did not deem the decrease significant (figure 7). Because of this,
the results for knockdown of inflammatory cytokine expression could be dampened and data
might not be representative of what would occur in a significant knockdown.
Nevertheless, MM6 cells show that a combination knockdown with shGLI3 and shp300
significantly decreases mRNA expression of all three proinflammatory cytokines (figure 8). This
treatment also results in the largest downregulation of CCL2 and TNFα compared to other
treatments. The p300 and combination knockdowns resulted in a similar decrease of IL-6 and
CCL2 expression. This supports the observation made previously in the overexpression qPCR
experiments. P300, but not GLI3, is responsible for cytokine expression in the MM6 cells.
In MM6 cells, all knockdown treatments result in a decrease in cytokine expression, but
the same cannot be said for qPCR experiments run with THP-1 cells. In the THP-1’s, cytokine
expression is seen to increase in many of the treatments, including the combination knockdown
(figure 9). Despite this, shp300 treatments decreased IL-6, CCL2, and TNFα expression. Also,
the combination knockdown did result in a decrease in TNFα and a significant decrease in CCL2
when compared to shGLI3 treatment alone. This could mean that shp300, but not shGLI3 is
responsible for decreasing cytokine expression in THP-1.
In U937, CCL2 is the only cytokine to have significantly decreased expression as a result
of the combination knockdown, compared to the scrambled shRNA (figure 10). TNFα does see a
non-significant decrease for the same treatment. For all three cytokines, shGLI3 treatment results
in lower expression than shp300 treatment. Additionally, the combination knockdown has a
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lower cytokine expression than either knockdown alone. Therefore, both GLI3 and p300 need to
be knocked down together to downregulate inflammatory cytokine expression in U937.
It is puzzling why some knockdown treatments actually increased expression of
proinflammatory cytokines because the opposite outcome was expected. Though shGLI3 and
shp300 were shown to successfully knockdown GLI3 and p300 respectively, the knockdown was
not very significant. This could mean that the GLI3 and p300 knockdown were not potent
enough to downregulate the proinflammatory cytokines. Western blots should be performed
alongside the qPCR experiments to confirm knockdown of GLI3 and p300. Also, a different
knockdown or knockout technique could be used (such as CRISPR) to ensure downregulation of
the target genes. Despite the uncertainty about the knockdown confirmation, the results of the
qPCR experiments seem to indicate that p300 is more important for cytokine expression than
GLI3 for some cell lines. In other instances, both GLI3 and p300 work together to modulate
inflammatory cytokine expression.
Something else to keep in mind is that overexpressing p300 should lead to the
upregulation of many cytokines, not just the ones studied here. Because p300 is a histone
acetyltransferase and will activate gene expression by acetylating target histones, it is reasonable
to expect that overexpressing p300 would upregulate GAPDH as well. This could mean that
samples containing a p300 overexpression would have naturally higher amounts of the GAPDH
housekeeping control, so a different control should be used that is not regulated by p300. This
would help with normalization and reliability of the data.

52

CCL2 Promoter Activation is Determined by GLI3 and p300
The CCL2 promoter has several candidate GLI binding sites, so I chose to analyze its
activation in the presence of GLI3 and p300. The CCL2 promoter was cloned into a luciferase
construct in order to perform dual luciferase assays using a dual luciferase assay system. The
readout for the luciferase assays is a ratio of firefly to renilla because the renilla construct is
unaffected by the CCL2 promoter and should be constitutively expressed. Therefore, it can be
used to normalize firefly measurements. Overexpressing GLI3 and p300 together results in a
significantly higher firefly to renilla ratio (firefly:renilla) in MM6 and U937 (figure 11). In both
cell lines, this increase is higher than all other treatments, supporting observations made in the
qPCR expriments. For MM6, p300 and GLI3 seem to have an additive effect on promoter
activation. In U937, p300, but not GLI3, are activating the CCL2 promoter. THP-1’s show no
significant difference between any treatments, indicating that GLI3 and p300 could play less of a
role in CCL2 activation within this cell line.
Knockdown dual luciferase experiments were ineffectual. CCL2 promoter activity was
not affected by treating with shGLI3, shp300, or the combination of both in MM6 and THP-1
(figure 12). In U937, there was actually an increase in promoter activity in the shp300 treatment
and combination knockdown. This is not supportive of the hypothesis and introduces questions
about how effective the shRNA constructs are at knocking down GLI3 and p300 for the
luciferase studies. The only cytokine promoter examined with the dual luciferase studies was
CCL2, so alternate proinflammatory cytokine promoters could be studied in the future to see if
GLI3 and p300 have a more dramatic effect on their activation. Additionally, single luciferase
could be performed and normalized to total protein content. This method of data acquisition
might lead to different results from a dual luciferase.
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CCL2 Cytokine Secretion is Modulated by GLI3 and p300
I also wanted to measure protein secretion being modulated by GLI3 and p300, so I ran
ELISAs that are designed to bind human CCL2. Both cell lines tested (THP-1 and U937) showed
the largest increase in CCL2 secretion for the combination overexpression of GLI3 and p300
(figure 13). However, only the increase in U937 is statistically significant. In both cell lines,
p300 overexpression alone also increased CCL2 secretion (more so than GLI3 alone). It could be
that p300 is more important than GLI3 for modulating cytokine release from these cells, but
GLI3 could still provide an additive effect to CCL2 secretion.
Knocking down only GLI3 led to a decrease of CCL2 secretion in THP-1 and a
significant decrease in CCL2 secretion in U937 (figure 14). Knocking down only p300 actually
increased CCL2 secretion when compared to the scrambled control, and the combination
knockdown decreased CCL2 secretion. This indicates that GLI3 is required for modulating
CCL2 secretion. These results are exactly opposite of what occurs to mRNA expression when
GLI3 is knocked down (figures 9 & 10). Therefore, GLI3 could be more associated with the
secretion of CCL2 than its initial expression.
Worth mentioning, MM6 cells are not included with the ELISA experiments because of
complications involved in restarting their growth from frozen stock. It is unknown how the
cytokine secretion of these cells would respond to knockdown/overexpression of GLI3 or p300.
Overall, CCL2 secretion in the THP-1 cells is more concentrated than secretion in the U937’s.
This is most likely due to innate differences in baseline secretion levels of this cytokine across
different cell lines, which could also change how overexpressing or knocking down GLI3 and
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p300 affects cytokine secretion. In the future, MM6 cells should be used for protein secretion
studies, and ELISA’s for other cytokines should also be performed.

Cloning GLI3 into TurboID
I attempted to clone the GLI3 coding sequence into the 3xHA-TurboID pRetrox plasmid
in order to use the TurboID proximity labeling technology to identify novel GLI3 binding
partners. I designed primers to amplify GLI3 from a plasmid (figure 16), and the primers
contained overhangs for the restriction enzymes EcoRI and NaeI. Then the primer-amplified
insert and TurboID were digested with the RE’s (figure 17). Next, I attempted to ligate GLI3 into
TurboID, transform competent bacteria with the ligation product, and check if any colonies
contained the insert inside the plasmid. PCR screening and digestion screening of the
transformed colonies didn’t yield any confirmation that ligation was successful (figures 18 &
19). To troubleshoot this issue, I digested the GLI3 sequence with NaeI and ran it on a gel (figure
20). The product was two distinct bands at half the size of the total GLI3 sequence, so I checked
the base pair sequence of GLI3 and found that NaeI and EcoRI both cut in the middle of the
GLI3 coding sequence. This disables traditional cloning as an approach to clone GLI3 into
TurboID.
To combat this problem, I sought help from Dr. Jeffers lab at UNH, and they suggested
Hifi DNA assembly cloning from NEB. This method doesn’t require digestion of the insert.
Instead, I designed primers with the NaeI restriction site and an overlap of the plasmid sequence
on their ends. The Hifi assembling machinery is able to recognize the plasmid overlaps and place
it in the correct place after digesting TurboID with only NaeI. Figure 21 shows the successful
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amplification of GLI3 with the new Hifi cloning primers. I digested TurboID with only NaeI and
only EcoRI and had a band show up for TurboID in both cases (figure 22). However, the
TurboID band in both instances is very faint, and concentrations from purification kits were also
very low. Despite this, I continued forward with ligating GLI3 into TurboID using the hifi
cloning assembly kit from NEB. I transformed cells with the ligation product, miniprepped
bacteria colonies and checked for successful ligation by digestion (figure 23). Still, none of the
colonies yielded a band for GLI3. I also had very low colony growth from the transformation, so
the ligation was not very effective.
My committee member, Dr. Wojchowski, recommended a company called VectorBuilder
that specializes in plasmid design, so I sent my materials to them. The plasmid should be
generated and able for use in our lab soon. Once it is prepared, future lab members can transfect
cells with the vector and isolate proteins that have been biotinylated in the cells. We can then
identify these proteins with mass spectrometry. The biotinylated proteins will be anything that is
in close proximity to GLI3 within the cell. Identifying novel GLI3 binding partners will open up
a myriad of new questions to pursue in our lab’s research.
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